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Abstract
HPV204 is the only newly identified Mupapillomavirus (Mu-PV) type in more than a decade.
To comprehensively characterize HPV204, we performed a detailed molecular analysis of
the viral genome and evaluated its clinical relevance in comparison to the other Mu-PVs,
HPV1 and HPV63. The 7,227-bp long genome of HPV204 exhibits typical genomic organi-
zation of Mu-PVs with eight open reading frames (ORFs) (E6, E7, E1, E2, E8, E4, L2, and
L1). We developed three type-specific quantitative real-time PCRs and used them to test a
representative collection (n = 1,006) of various HPV-associated benign and malignant neo-
plasms, as well as samples of clinically normal cutaneous, mucosal, and mucocutaneous
origins. HPV204, HPV1, and HPV63 were detected in 1.1%, 2.7%, and 1.9% of samples
tested, respectively, and were present in skin and mucosa, suggesting dual tissue tropism
of all Mu-PVs. To evaluate the etiological role of Mu-PVs in the development of HPV-associ-
ated neoplasms, Mu-PV viral loads per single cell were estimated. HPV1 and HPV63 were
present in high viral copy numbers in 3/43 and 1/43 cutaneous warts, respectively, and were
identified as the most likely causative agents of these warts. HPV204 viral load was
extremely low in a single HPV204-positive cutaneous wart (7.4 × 10−7 viral copies/cell).
Hence, etiological association between HPV204 and the development of cutaneous warts
could not be established. To the best of our knowledge, this is the first study to evaluate the
genetic variability of Mu-PVs by sequencing complete LCR genomic regions of HPV204,
HPV1, and HPV63. We detected several nucleotide substitutions and deletions within the
LCR genomic regions of Mu-PVs and identified two genetic variants of HPV204 and HPV63
and five genetic variants of HPV1.
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Introduction
Human papillomaviruses (HPVs) are small, double-stranded and highly diverse DNA
viruses of the Papillomaviridae family, which typically infect human epithelial cells [1].
HPVs are etiologically associated with the development of various benign and malignant
neoplasms in humans; however, the majority of HPV infections are transient and/or latent
[2, 3]. Based on the identity of the complete L1 gene nucleotide sequences, HPVs are hierar-
chically classified into genera, species, and types. HPV types exhibiting at least 60% nucleo-
tide sequence identity within the L1 gene belong to the same genus, whereas HPV types with
60 to 70% nucleotide sequence similarity constitute different viral species [1]. As of March
31st, 2017, 206 HPV types were officially recognized by the HPV Reference center at the Kar-
olinska Institute in Sweden (http://www.hpvcenter.se/html/refclones.html). Currently, all
HPV types are classified into five genera: Alphapapillomavirus (Alpha-PV), Betapapilloma-
virus (Beta-PV), Gammapapillomavirus (Gamma-PV), Mupapillomavirus (Mu-PV), and
Nupapillomavirus (Nu-PV) [4, 5].
Contrary to the rapidly growing Beta- and Gamma-PV genera, the Mu-PV genus currently
consists of only three HPV types: HPV1, HPV63, and HPV204 [5, 6]. In 1980, HPV1 was iso-
lated and cloned from tissue specimens of deep plantar warts [7, 8] and its complete nucleotide
sequence was obtained 2 years later (GeneBank accession numbers V01116 and NC_001356)
[9]. HPV63 (GeneBank accession number X70828) was originally identified in punctate kera-
totic lesions of the foot in 1993 [10]. At the nucleotide level, HPV63 displayed 69.0% sequence
homology with the HPV1 L1 open reading frame (ORF) and thus constituted a distinct species
(Mu-2) within the Mu-PV genus [10]. Identification and preliminary characterization of a
novel Mu-PV type HPV204 has been recently described by our research group [6, 11]. Briefly,
in 2009 we identified a partial 200-bp L1 gene sequence exhibiting the highest sequence simi-
larity with Mu-PVs HPV1 and HPV63 in a skin swab sample using the broad-spectrum FAP
primer system [11–13]. In 2014, the complete viral genome of a putatively novel Mu-PV type
was amplified from a swab of the anal canal obtained from a 36-year-old male patient with
HPV53-positive anal warts. The corresponding amplicon was cloned into a plasmid vector
and sequenced by primer walking strategy [6]. Nucleotide sequence (GeneBank accession
number KP769769) of the complete viral genome was submitted to the HPV Reference Center
at the Karolinska Institute. The sequence was reconfirmed and the novel Mu-PV type was offi-
cially assigned the number HPV204 in January 2015 (http://www.hpvcenter.se/html/refclones.
html). According to the International Committee on Taxonomy of Viruses (ICTV), HPV204
constitutes a distinct species (Mu-3) within the Mu-PV genus, since the L1 nucleotide
sequence of HPV204 exhibits only 66.3% and 66.7% sequence identity with L1 genes of HPV1
and HPV63, respectively (https://talk.ictvonline.org/files/ictv_official_taxonomy_updates_
since_the_8th_report/m/animal-dna-viruses-and-retroviruses?pi4565=2). HPV204 represents
the only novel Mu-PV type in more than a decade, despite the use of several modern molecular
methods to identify potentially novel HPVs in recent years [6, 11, 14].
To date, tissue tropism of HPV204 has not been described in peer-reviewed literature,
whereas it has been shown that HPV1 and HPV63 typically infect keratinocytes of eccrine
ducts in the palmoplantar skin and are hence considered cutaneotrophic [15, 16]. HPV1 was
also identified in an oral sample in a recent metagenomics study [17], suggesting that Mu-PVs
exhibit broader tissue tropism than previously expected.
Amplification and sequencing of eight HPV1 L1 amplicons obtained from scrapings of pso-
riatic lesions revealed a single nucleotide polymorphism (SNP) (A5793C) within the L1 gene
of HPV1 [18]. However, the long control region (LCR) exhibits the highest level of diversity
among HPVs [19] and its variability in Mu-PVs has not been described prior to this study.
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In this study, we present a detailed molecular characterization of HPV204 in comparison to
HPV1 and HPV63. To determine the tissue tropism and potential clinical significance of Mu-
PVs, we systematically investigated the prevalence of HPV204, HPV1, and HPV63 and deter-
mined corresponding viral loads in Mu-PV–positive samples in a representative collection of
clinical specimens commonly associated with HPV infection, using three newly developed
quantitative type-specific real-time PCRs (RT-PCRs). In addition, to the best of our knowl-
edge, this is the first study to assess genetic diversity of Mu-PVs by amplifying and sequencing
their complete LCR genomic regions.
Materials and methods
Molecular characterization of HPV204, HPV1, and HPV63
We used the ORF Finder Tool (https://www.ncbi.nlm.nih.gov/gorf/gorf.html) to identify dis-
tinct ORFs of HPV204. In addition, viral genomic regions and protein functional domains
were characterized in detail using previously published data and several freely available online
applications [20–25]. The same protocol was used to characterize as-yet undescribed func-
tional domains of HPV1 and HPV63 [9, 10, 26, 27].
HPV204, HPV1, and HPV63 type-specific quantitative RT-PCRs
All type-specific primer pairs and probes (Table 1) were designed using the freely available
online application Primer3Plus (http://primer3plus.com/cgi-bin/dev/primer3plus.cgi). To
avoid potential cross-reactivity with non-targeted sequences, the specificity of each primer and
probe was verified using NCBI Blast (https://blast.ncbi.nlm.nih.gov/Blast.cgi).
The HPV204 type-specific quantitative RT-PCR was performed using a QuantiTect Probe
PCR kit (Qiagen, Hilden, Germany). The reaction mixture consisted of 5 μl of sample DNA,
10 μl of 2X QuantiTect Probe RT-PCR Master mix, 0.4 μM of each primer, 0.2 μM of the
probe, and water up to the final reaction volume of 20 μl. The assay was performed on a Light-
Cycler 480 II RT-PCR Instrument (Roche Diagnostics, Mannheim, Germany) under the fol-
lowing cycling conditions: an initial 15 min incubation step at 95˚C (ramp rate 4.4˚C/s),
followed by 45 cycles of (i) 15 s at 95˚C (2.2˚C/s), (ii) 60 s at 60˚C (2.2˚C/s), and a final cooling
step with a 30 s hold at 40˚C (2.2˚C/s). The fluorescence signal was measured during each
annealing/extension step on the 510 nm channel.
Table 1. General characteristics of primers and probes designed for HPV204, HPV1, and HPV63 type-specific quantitative real-time PCRs.
HPV (targeted gene) Primer/probea nucleotide sequence (50–30) Amplicon size (bp) Nucleotide position
HPV204 (L1) TTTAATCCTGAAACAGAACGCTT 133 5,461–5,483
ATCTAGCAGGATTTTCCACATCA 5,593–5,571
FAM-AAGTAGTGTTACCGGGCATCCTA-BHQ 5,532–5,554
HPV1 (L1) AGCAACATGCAAATATCCTGATT 148 6,103–6,125
TTGTGGGACTGCCTCCTTATC 6,250–6,230
YAK-GCGAGCAAATGTATACCAGGCACT-BHQ 6,180–6,203
HPV63 (E2) TCCTGTCAATAGCTCCCCACT 108 3,219–3,239
GACCCCTTCGTCTCTGCTTT 3,326–3,307
FAM-ACACCAACCCAGCCACCCAAG-BHQ 3,263–3,283
Genbank accession numbers: KP769769 (HPV204), V01116 (revised; HPV1), and X70828 (HPV63).
a Real-time amplification of targeted Mu-PVs was monitored using 50 dually labeled hydrolysis probes.
https://doi.org/10.1371/journal.pone.0175892.t001
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HPV1 and HPV63 type-specific quantitative RT-PCRs were performed using a LightCy-
cler480 Probes kit (Roche Diagnostics). The reaction mixture for the detection of HPV1 con-
sisted of 5 μl of sample DNA, 10 μl of 2X LightCycler480 Probes Master, 0.6 μM of each
primer, 0.4 μM of the probe, and water up to the final reaction volume of 20 μl. The reaction
mixture for the detection of HPV63 consisted of 5 μl of sample DNA, 10 μl of 2X LightCy-
cler480 Probes Master, 0.5 μM of each primer, 0.2 μM of the probe, and water up to the final
reaction volume of 20 μl. Both assays were performed on a LightCycler 480 II RT-PCR Instru-
ment (Roche Diagnostics), under the following cycling conditions: an initial 10 min incuba-
tion step at 95˚C (4.4˚C/s), followed by 45 cycles of (i) 10 s at 95˚C (4.4˚C/s), (ii) 30 s at 60˚C
(2.2˚C/s), (iii) 1 s at 72˚C (4.4˚C/s), and a final cooling step with a 30 s hold at 40˚C (2.2˚C/s).
Fluorescence signals of HPV1 and HPV63 were measured during each extension step on 560
and 510 nm channels, respectively.
Triplicates of 10-fold serial dilutions of HPV204, HPV1, and HPV63 reference plasmids,
ranging from 1 × 109 to 1 × 10−1 DNA copies/reaction, were used to evaluate analytical sensi-
tivity of each type-specific RT-PCR. Dynamic ranges of HPV204 and HPV63 RT-PCRs were
nine orders of magnitude, and enabled reliable discrimination of 109 to one viral copy/reac-
tion, whereas the dynamic range of the HPV1 RT-PCR was eight orders of magnitude and reli-
ably discriminated 109 to 10 viral copies/reaction. The detection limit of HPV204 and HPV63
RT-PCRs was at least one viral copy/reaction and for HPV1 RT-PCR at least 10 viral copies/
reaction. The standard curve correlation coefficients (R2) calculated were as follows: 0.998 for
HPV204 RT-PCR and 0.999 for both HPV1 and HPV63 RT-PCRs. All RT-PCRs had high
amplification efficiencies of 100% (HPV204), 94.4% (HPV1), and 99.2% (HPV63). Specificity
and cross-reactivity of HPV204, HPV1, and HPV63 RT-PCRs were evaluated using serial dilu-
tions of Mu-PV reference plasmids, ranging from 109 to 104 DNA copies/reaction: HPV204
RT-PCR was evaluated using HPV1 and HPV63 reference plasmids, HPV1 RT-PCR using
HPV204 and HPV63 reference plasmids, and HPV63 RT-PCR using HPV204 and HPV1 ref-
erence plasmids. In addition, the specificity of all HPV204, HPV1, and HPV63 RT-PCR ampli-
cons was confirmed by direct Sanger sequencing.
Tissue tropism and viral load of Mu-PVs
Using three type-specific quantitative RT-PCRs, the clinical significance and tissue tropism
of Mu-PVs was assessed by testing a representative collection of clinical specimens most
commonly associated with HPV infection (n = 1,006). The sample collection included histo-
logically confirmed tissue specimens of benign neoplasms of cutaneous (cutaneous warts),
mucocutaneous (anogenital warts) and mucosal origin (laryngeal and conjunctival papillo-
mas) as well as mucosal (cervical, oral/oropharyngeal, and conjunctival squamous cell carci-
noma (SCC)) and cutaneous (SCC and basal cell carcinoma (BCC) of the skin) HPV-related
malignant neoplasms. To determine whether Mu-PVs are also present in clinically normal
cutaneous, mucocutaneous, and mucosal epithelia, eyebrow hair follicles, swabs of the penile
surface, swabs of the anal canal (obtained from patients with hemorrhoids, anal fissure, and
anal warts), swabs of the oral cavity, nasopharyngeal swabs, and cervical swabs were also
included in the sample collection. To evaluate the potential role of Mu-PVs in the develop-
ment of different neoplasms, HPV204, HPV1, and/or HPV63 viral loads were estimated in
all HPV204-, HPV1-, and HPV63-positive tissue samples. The concentration of beta-globin
was determined using a quantitative RT-PCR amplifying a 150-bp fragment of the human
beta-globin gene, and was used in combination with HPV type-specific RT-PCRs to deter-
mine the ratio between the number of viral copies and human diploid cells, as described pre-
viously [24, 28].
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PLOS ONE | https://doi.org/10.1371/journal.pone.0175892 April 20, 2017 4 / 17
The presence of other and/or additional mucosal and cutaneous wart-associated HPV types
was determined using two previously described in-house PCR protocols [24, 25]. Briefly, we
used primer pair HVP2/B5 to detect cutaneous Alpha- (HPV2, HPV3, HPV10, HPV27,
HPV28, HPV29, HPV57, and HPV77), Mu- (HPV1 and HPV63), and Nu-PVs (HPV41),
whereas a real-time PCR with a primer set HP1,3_F2/HP2_F2/HP_iLC and HP_LNA probe
was used to detect low-risk Alpha-PVs HPV6 and HPV11. For both PCR protocols, 5 μl of
sample DNA per 25 μl of reaction mixture was used. Amplicons obtained with a primer pair
HVP2/B5 were analyzed on a 2.0% agarose gel. All specific amplicons were subsequently
sequenced and HPV types were determined according to the NCBI Blast analysis (https://blast.
ncbi.nlm.nih.gov/Blast.cgi).
Amplification and sequencing of LCR genomic regions of HPV204,
HPV1, and HPV63
In order to amplify complete LCR genomic regions of Mu-PVs, HPV204-, HPV1-, and
HPV63-specific primer pairs (S1 Table) were designed using the Primer3Plus application. Sin-
gle primer pairs were used for the amplification of the 510-bp and 555-bp long LCR genomic
regions of HPV204 and HPV63, respectively. If no PCR specific amplicon was obtained, sev-
eral overlapping primer pairs were additionally used in different combinations to obtain
shorter PCR amplicons. Three sets of overlapping primers were initially used to amplify the
complete LCR genomic region of HPV1 (979-bp) and up to seven additional primer pair com-
binations were used if the initial PCRs yielded no specific amplicons. Using FastStart High
Fidelity PCR System (Roche Diagnostics), the reaction mixture consisted of 5 μl of sample
DNA, 2.5 μl of 10 x FastStart High Fidelity Reaction Buffer, 200 μM of dNTP mix, 0.4 μM of
each primer, 1.25 U of FastStart High Fidelity Enzyme Blend, and water up to the final reaction
volume of 25 μl. Amplification of the LCR genomic region of all Mu-PVs was performed on a
Veriti Thermal Cycler (Thermo Fisher Scientific, Waltham, MA, USA) under the following
conditions: an initial incubation at 95˚C for 2 min, followed by 45 cycles of (i) 30 s at 95˚C, (ii)
30 s at 54˚C, (iii) 30 s at 72˚C, and 7 min incubation (final elongation) at 72˚C with a final
cooling step at 4˚C. All PCR amplicons were evaluated on a 2.0% agarose gel and sequenced in
both directions using the same primers as for PCR. Analytical sensitivity of HPV LCR type-
specific PCRs was evaluated using 10-fold serial dilutions of HPV204, HPV1, and HPV63 ref-
erence plasmids, ranging from 1 × 109 to 1 × 10−1 DNA copies/reaction. The detection limit of
shorter PCR amplicons (209-bp to 359-bp) was determined to be 10 viral copies/reaction for
HPV204 and HPV63, and 100 viral copies/reaction for HPV1.
Complete LCR genomic regions of HPV204, HPV1 and HPV63 were assembled using the
Vector NTI Advance v11 program package (Invitrogen, Carlsbad, CA, USA). To identify
potential SNPs and/or deletions, complete LCR genomic regions were subsequently aligned
with HPV204, HPV1, and HPV63 reference sequences obtained from the Papillomavirus Epi-
steme (PaVE) (https://pave.niaid.nih.gov/), and with all other available Mu-PV sequences in
the Genbank database (Genbank accession numbers NC_001356 and U06714, both HPV1).
Ethics statement
Our study was conducted in compliance with the Helsinki Declaration. A total of 1,006 clinical
samples were collected either in our past or ongoing studies, which were all approved by the
Ethics Committee of the Ministry of Health of Republic of Slovenia (consent numbers 34/11/
06, 45/04/07, 131/06/07, 174/05/09, 83/11/09, 97/11/09, 100/12/09, 53/09/10, 109/08/12, and
63/10/13). None of the samples tested were obtained solely for the purpose of this study. All
patients provided written informed consent prior to the beginning of the study. To assure
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patient confidentiality, all samples were coded and analyzed anonymously. The protocol and
the use of all DNA samples were approved by the Institutional Review Board of the Institute of
Microbiology and Immunology, Faculty of Medicine, University of Ljubljana.
Results and discussion
Molecular characterization of HPV204 in comparison to HPV1 and
HPV63
This study presents a detailed characterization of the complete genome of the novel Mu-PV
HPV204, which is only the third officially recognized Mu-PV to date. As shown in Fig 1,
HPV204 (7,227-bp) exhibits a genomic organization similar to those of previously described
members of the Mu-PV genus (HPV1: 7,816-bp, HPV63: 7,348-bp) [6, 9, 10], with ORFs for
six early (E6, E7, E1, E2, E8, and E4) and two late genes (L1 and L2), and a GC ratio of 37.8%.
Genomic positions of viral genes and non-coding LCR genomic regions of Mu-PVs are pre-
sented in S2 Table.
The most important putative viral motifs and functional domains of Mu-PVs are pre-
sented in S3 Table. E6 proteins of all Mu-PVs contain two zinc-binding domains, which are
crucial for the preservation of structural and biological functions of the E6 oncoprotein [29,
30]. Interestingly, the E7 zinc-binding domain of HPV204 (CXXC(X)28CXXC) is shorter by
one amino acid (aa) when compared to the same motif in most HPVs. In addition to
HPV204, this particular domain was only identified in HPV90 (Alpha-PV), whereas it is
more commonly found in E7 proteins of animal PVs (data not shown). All Mu-PVs contain
a pRB-binding site within their E7 proteins and are thus capable of inactivating the cell reti-
noblastoma protein (pRB) [31].
At the N-termini of the E1 protein, HPVs typically contain a highly conserved bipartite-like
nuclear localization signal (NLS) and a leucine-rich Crm1-dependant nuclear export signal
(NES), which together enable shuttling of the E1 protein between the cell nucleus and cyto-
plasm [32–34]. As shown in S3 Table, both motifs are present in E1 proteins of all Mu-PVs;
however, we have identified an aa substitution (L94I) in the first position of NES of HPV1.
The E1 proteins of all Mu-PVs contain several cdk-phosphorylation sites. In addition, a con-
sensus cyclin-binding motif (RXL) was identified at the N-termini of the E1 proteins of
Fig 1. Genomic organization of HPV204 with genomic positions of viral early (E6, E7, E1, E2, E8, and
E4) and late genes (L1 and L2). The non-coding long control region (LCR) is positioned between the L1 and
E6 genes.
https://doi.org/10.1371/journal.pone.0175892.g001
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HPV204 and HPV1, whereas HPV63 harbors a R117K substitution in the first position of its
cyclin-binding motif. The cyclin-binding motif is necessary for interaction between the E1 and
cyclin/cyclin-dependent kinase (cdk) complex and it has been shown that mutations in the
consensus cyclin-binding motif and/or cdk-phosphorylation site(s) significantly reduce initia-
tion of viral DNA replication [35–37]. In addition, the E1 proteins of all Mu-PVs contain a
conserved ATP-binding site, which has two important structural roles: (i) it is crucial for for-
mation of the E2-binding surface, and (ii) upon binding of ATP-Mg, it facilitates conforma-
tional changes in the E1 protein that occur during binding to the origin of replication [38].
As shown in S3 Table, we have identified a conserved leucine zipper domain, which is
required for dimerization of the protein [39], at the C-terminus of the HPV204 E2 protein.
Interestingly, although no conserved leucine zipper domain was observed at the C-terminus of
the HPV1 E2 protein, one was identified at its N-terminus. According to the detailed analysis
of all available HPV E2 reference aa sequences obtained from PaVE, HPV1 represents the only
HPV type that harbors a leucine zipper domain at the N-terminus (data not shown). In con-
trast, no conserved leucine zipper domain was observed in the E2 protein of HPV63.
In addition to the full-length E2 protein, we identified a fusion protein E8^E2 consisting of
the E8 gene product and C-terminal domain of the E2 gene. The E8^E2 protein not only
inhibits viral transcription and replication of high-risk Alpha-PVs but it also suppresses
genome replication of HPV1 and HPV8 (Beta-PV) in human keratinocytes via interaction
with NCoR/SMRT corepressor complexes [40, 41]. As shown previously, the KLK motif of the
E8 protein, which is required for the NCoR/SMRT-E8^E2 interaction, is highly conserved
among all members of the Mu-PV genus [41, 42].
Similar to other HPVs, E4 ORFs of all members of the Mu-PV genus are located within the
larger E2 ORFs and have their own start codons (Fig 1) [9, 10, 25, 43, 44]. However, identifica-
tion of characteristic donor (AAG/GUASNR) and acceptor (GUYACYAG/YU) RNA splicing
sites suggests that E4 proteins of all Mu-PVs are translated from a spliced E1^E4 mRNA with
the initiation codon for E4 gene expression originating from the E1 ORF [24, 25, 43–45].
E1^E4 proteins of HPV204, HPV1, and HPV63 contain 11.5% (aa 15/131), 11.2% (aa 15/134),
and 11.0% (aa 17/154) proline residues, respectively.
A consensus furin cleavage motif as well as a transmembrane-like domain [27] were identi-
fied at the N-termini of the L2 proteins of all Mu-PVs (S3 Table). Both domains are crucial for
HPV infectivity because cleavage of the L2 protein at the highly conserved furin cleavage site
promotes conformational changes of the viral capsid, while the transmembrane-like domain
enables translocation of the viral genome across the endosomal membrane [27, 46]. In addi-
tion, a single canonical polyadenylation site necessary for regulation of early viral transcripts
[47] is located at N-termini of L2 proteins of all Mu-PVs, whereas HPV1 contains an addi-
tional polyadenylation site in the middle of L2 ORF [9].
The LCR genomic region of HPV204 is positioned between the L1 and E6 genes (Fig 1, S2
Table) and is relatively short (510-bp) in comparison to the LCR genomic region of HPV1
(979-bp). As shown in S3 Table, HPV204 and HPV1 contain two polyadenylation sites for late
viral transcripts within their LCR genomic regions, whereas a single late polyadenylation site
was observed in HPV63. LCR genomic regions of all Mu-PVs harbor a putative TATA
box motif of the E6 gene promoter and two to three conserved E2-binding motifs. An 18-bp
long palindrome sequence with a putative E1-binding site was identified within the LCR geno-
mic region of each Mu-PV, most likely representing origin of replication [25, 48]. As described
in a previous publication [26], the LCR genomic region of HPV1 contains binding sites for
several transcriptional factors (e.g., NF-1, AP-1, and C/EBP). In addition, we have identified
AP-1- and NF-1-binding sites in the LCR genomic region of HPV204, whereas the LCR geno-
mic region of HPV63 contains binding sites for NF-1 and C/EBP.
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Clinical relevance and tissue tropism of HPV204, HPV1, and HPV63
To evaluate the potential clinical relevance and tissue tropism of Mu-PVs, we tested a repre-
sentative collection of different HPV-associated clinical samples using three highly sensitive
and specific quantitative type-specific RT-PCRs. Our sample collection consisted of a total of
1,006 clinical samples representing a range of the most important HPV-associated benign and
malignant neoplasms (Table 2). In addition, several samples of normal mucosa and skin were
tested to determine potential anatomical niches of Mu-PVs.
As shown in Table 2, HPV204, HPV1, and HPV63 were detected in a total of 11/1,006
(1.1%), 27/1,006 (2.7%), and 19/1,006 (1.9%) samples, respectively, suggesting a relatively low
prevalence of Mu-PVs in samples of various etiologies obtained from different anatomical
locations. Similar to Beta- and Gamma-PVs [24, 25, 49–51], Mu-PVs were detected in clinical
samples of cutaneous origin (eyebrow hair follicles and cutaneous warts), mucosal origin
(nasopharyngeal swabs, swabs of the oral cavity, and cervical swabs negative for intraepithelial
lesion or malignancy), and mucocutaneous origin (anogenital warts and swabs of the anal
canal and penile surface). In accordance with a recent metagenomics study [17], our results
suggest that infections with Mu-PVs are not strictly limited to cutaneous epithelia and that all
members of the Mu-PV genus exhibit dual tissue tropism.
As shown in Table 2, HPV204, HPV1, and HPV63 were detected in 1/43, 21/43, and 9/43
cutaneous warts, respectively. In contrast to previous studies [52, 53], multiple HPV types
were detected in 15/22 (68.2%) cutaneous warts and, interestingly, HPV1 was concurrently
detected in all HPV63-positive samples (Table 3). Kohler et al. [54] have shown that, in cuta-
neous warts with mixed infections, clinically latent HPV infections can be discerned from a
productive infection with a cutaneous wart–associated HPV type based on the viral load
Table 2. The prevalence of HPV204, HPV1, and HPV63 in clinical samples.
Type of
epithelia
Anatomical location/
histology (sample type)
No. of samples
tested
No. of HPV204-positive
samples (%)
No. of HPV1-positive
samples (%)
No. of HPV63-positive
samples (%)
Mucosal Nasopharynx (swabs) 110 0 2 (1.8) 3 (2.7)
Oral cavity (swabs) 105 0 0 2 (1.9)
Laryngeal papilloma (fresh
tissue)
31 0 0 0
Oral and oropharyngeal SCC
(FFPE)
20 0 0 0
Conjunctival papilloma (FFPE) 30 0 0 0
Conjunctival carcinoma
(FFPE)
34 0 0 0
Cervix (swabs) 116 1 (0.8) 0 0
Cervical cancer (FFPE) 59 0 0 0
Cutaneous Eyebrows (hair follicles) 110 0 1 (0.9) 4 (3.6)
Cutaneous warts (fresh tissue,
FFPE)
43 1 (2.3) 21 (48.8) 9 (20.9)
SCC (FFPE) 43 0 0 0
BCC (FFPE) 45 0 0 0
Mucocutaneous Anogenital warts (fresh tissue) 40 0 3 (7.5) 0
Anal canal (swab) 110 4 (3.6) 0 1 (0.9)
Penile surface (swab) 110 5 (4.5) 0 0
Total 1,006 11 (1.1) 27 (2.7) 19 (1.9)
SCC, squamous cell carcinoma; BCC, basal cell carcinoma; FFPE, formalin-fixed paraffin-embedded tissues.
https://doi.org/10.1371/journal.pone.0175892.t002
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determination. Thus, the causative HPV types are usually present in cutaneous warts in high
viral copy numbers, ranging from 51 viral copies/cell to 3.5 × 105 viral copies/cell [54]. High
viral copy numbers of HPV1 (range 8.5 × 103 to 5.2 × 104 viral copies/cell) were detected in
three cutaneous warts and, because HPV1 was also the only cutaneous wart-associated HPV
type identified, it most likely represented the causative agent of these warts. In addition, the
viral load of HPV63 was high (3.9 × 102 viral copies/cell) in one HPV63-positive cutaneous
wart, suggesting that HPV63 was etiologically linked with the development of this wart, in
spite of the co-presence of HPV1 in low viral copy numbers. However, the viral load of
HPV1 and HPV63 was low in other cutaneous warts, ranging from 3.2 × 10−6 to 3.6 × 10−2
Table 3. Characteristics of HPV204-, HPV1-, and HPV63-positive tissue samples.
Clinical sample Location Sample type Sample number Mu-PV typea Viral load (viral copies/cell) Other HPV types
Cutaneous warts Foot Fresh tissue ZU-7 HPV1 5.2 × 104 /
NA FFPE ZU-13 HPV1 3.9 × 104 /
Sole of the foot Fresh tissue P00057 HPV1 1.8 × 10−2 HPV57
HPV63 2.5 × 10−5
Hand Fresh tissue P00061 HPV1 8.5 × 103 /
Sole of the foot Fresh tissue P00062 HPV1 2.1 × 10−2 HPV27
HPV63 1.7 × 10−5
Hand Fresh tissue P00063 HPV1 5.1 × 10−4 HPV27
Hand Fresh tissue P00064 HPV1 1.5 × 10−4 HPV2
HPV63 7.3 × 10−3
Sole of the foot Fresh tissue P00065 HPV1 1.9 × 10−3 HPV2, HPV27
Sole of the foot Fresh tissue P00067 HPV1 3.6 × 10−2 HPV57
HPV63 1.1 × 10−2
Sole of the foot Fresh tissue P00070 HPV1 7.0 × 10−4 /
HPV63 3.5 × 10−6
Sole of the foot Fresh tissue P00071 HPV1 1.9 × 10−4 /
HPV63 3.9 × 102
Hand Fresh tissue P00074 HPV1 8.1 × 10−4 /
HPV63 3.7 × 10−4
Hand Fresh tissue P00076 HPV1 1.1 × 10−3 HPV57
Hand Fresh tissue P00077 HPV1 6.2 × 10−3 /
HPV63 1.4 × 10−5
Finger (hand) Fresh tissue P00078 HPV1 2.5 × 10−5 HPV57
HPV63 3.2 × 10−6
Finger (hand) Fresh tissue P00079 HPV1 3.8 × 10−4 HPV57
Finger (hand) Fresh tissue P00116 HPV204 7.4 × 10−7 HPV57
NA FFPE P00162 HPV1 2.3 × 10−2 HPV57
NA FFPE P00170 HPV1 6.4 × 10−4 /
NA FFPE P00172 HPV1 6.7 × 10−4 /
NA FFPE P00173 HPV1 4.3 × 10−3 /
NA FFPE P00176 HPV1 4.3 × 10−4 /
Anogenital warts NA Fresh tissue 271 HPV1 1.9 × 10−5 HPV6
NA Fresh tissue 301 HPV1 3.2 × 10−5 HPV6
NA Fresh tissue 336 HPV1 5.9 × 10−6 HPV11
Mu-PV, Mupapillomavirus type; NA, not available; FFPE, formalin fixed, paraffin embedded; /, no additional HPV types detected.
a The presumed Mu-PV types causing the cutaneous warts are written in bold.
https://doi.org/10.1371/journal.pone.0175892.t003
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viral copies/cell. Similarly, the viral load of HPV204 in the only HPV204-positive cutaneous
wart was extremely low (7.4 × 10−7 viral copies/cell), suggesting clinically latent infection
with HPV204. In 11/18 (61.1%) cutaneous warts with low viral load of Mu-PVs, we concomi-
tantly detected cutaneous wart–associated Alpha-PVs (HPV2, HPV27, and HPV57), which
were the most probable etiological agents of these warts [52, 54]. As shown in Table 3, we did
not detect any additional cutaneous wart-associated HPV types in seven cutaneous warts,
suggesting the involvement of rarer cutaneous wart-associated HPV types, such as HPV125,
HPV179, and HPV184 [24, 44] or potentially novel HPV types. Second, the low viral load of
Mu-PVs in these lesions could be a result of the dilution of Mu-PV–infected cells with het-
erogeneous, non-targeted cell populations. Hence, fluorescent in situ hybridization or laser
capture microdissection in combination with type-specific PCR could provide reliable deter-
mination of the causative HPV types within the lesions [55, 56]. The relatively low prevalence
of HPV1- and HPV63-induced cutaneous warts in our study could be explained by the cuta-
neous warts’ locations, patient selection, and distinct clinical and histopathological manifes-
tations of infection with Mu-PVs in different age groups [15, 16, 53]. Namely,
HPV1-induced cutaneous warts are more prevalent in younger children [53], whereas all
cutaneous wart samples in this study were obtained from adult patients, in whom Alpha-PVs
are the usual etiological agents [54]. In addition, the majority of cutaneous warts were
obtained from hands, whereas HPV1 and HPV63 typically cause plantar warts [16]. More-
over, to the best of our knowledge, HPV63-induced warts are rare and have been described
only on the sole of the foot [10, 15, 16, 52, 53]. Interestingly, the only HPV63-positive cutane-
ous wart with high viral load in our study was located on a hand, suggesting HPV63 may also
sporadically cause hand warts.
Although it has previously been shown that eyebrow hair follicles and the oral and nasal
mucosa represent important reservoirs of cutaneous HPVs [49, 50, 57, 58], the overall preva-
lence of Mu-PVs in these samples was surprisingly low in our study (Table 2), ranging from
0% to 3.6% (eyebrow hair follicles), 0% to 1.9% (swabs of the oral mucosa), and 0% to 2.7%
(swabs of the nasal mucosa). In a recent study by de Koning et al. [53], a relatively high preva-
lence of HPV1 (59.2%) and HPV63 (25.4%) was observed in swabs of clinically normal skin
obtained from children with and without cutaneous warts, suggesting the ubiquitous presence
of HPV1 and HPV63. However, the use of swabs of non-hairy skin surfaces, such as palms,
soles, and the forehead, might have contributed to increased detection rates observed in previ-
ous studies, because these areas contain numerous eccrine glands, which represent typical tar-
gets of HPV1 and HPV63 [15, 16, 53].
HPV1 was detected in 3/40 (7.5%) anogenital warts; however, due to low HPV1 viral copy
numbers, ranging from 5.9 × 10−6 to 3.2 × 10−5 viral copies/cell (Table 3), and the co-detection
of well-established causative agents of these lesions (HPV6 and HPV11), these anogenital
warts could not be etiologically attributed to infection with HPV1 [54, 59]. As shown previ-
ously [60], HPV1 most probably represented a superficial contaminant, although laser capture
microdissection coupled with PCR or fluorescent in situ hybridization should be used to deter-
mine whether HPV1 is also capable of infecting lower portions of the anogenital epithelia,
such as the stratum spinosum and stratum basale [55, 56].
HPV204 was most commonly detected in swabs of the penile surface (5/110, 4.5%) and anal
canal (4/110, 3.6%), suggesting its preference for anogenital mucocutaneous epithelia
(Table 2). To the best of our knowledge, we detected HPV63 in the anal canal for the first time.
In contrast, HPV1 was not detected in any of the swab specimens of the anal canal tested.
To the best of our knowledge, no prior studies evaluated the presence of Mu-PVs in cervical
swab samples. Interestingly, HPV204 was the only member of the Mu-PV genus detected in
cervical swabs negative for intraepithelial lesion or malignancy (1/116; 0.8%). Thus, HPV204
Molecular characterization of Mupapillomavirus types
PLOS ONE | https://doi.org/10.1371/journal.pone.0175892 April 20, 2017 10 / 17
may cause clinically latent infections of the cervical mucosa as observed previously for some
members of the Gamma-PV genus [25].
Data regarding the carcinogenic potential of HPV1 and HPV63 are scarce. In a recent
study, HPV1 was detected in 1/238 BCC samples; however, no associations were found
between HPV1 and an increased risk for the development of BCC [61]. In our study, none of
the 201 malignant neoplasms tested positive for the presence of HPV204, HPV1, or HPV63
(Table 2). Several factors could account for these observations. First, our sample collection
included a relatively large number of malignant neoplasms, which are not uniformly caused by
HPV infection (e.g., SCC and BCC of the skin, conjunctival carcinoma, and oral/oropharyn-
geal SCC). Second, the fixation procedure in FFPE samples could have significantly degraded
the DNA and, consequently, latent Mu-PV infection(s) with extremely low viral copy numbers
might not be detected [24, 62]. However, we optimized all type-specific PCRs for Mu-PV
detection from FFPE samples and, as shown in Table 3, viral loads were comparable regardless
of the sample type (FFPE vs. fresh tissue sample). Thus, despite some limitations, our data do
not support the etiologic implication of Mu-PVs in the development of HPV-associated
malignancies.
Genetic variability of the LCR genomic regions of HPV204, HPV1, and
HPV63
In addition, we wanted to evaluate the genetic variability of Mu-PVs and to identify genetic
variants with potential clinical or anatomical specificities. To the best of our knowledge, this is
the first study to evaluate genetic variability of Mu-PVs by amplifying LCR genomic regions of
HPV204, HPV1, and HPV63. Sanger sequencing of the obtained LCR genomic regions was
performed and genetic variability of each Mu-PV isolate was defined as the number of SNPs/
deletions per a complete LCR genomic region.
Despite using highly sensitive PCR(s), which were designed to amplify viral DNA in clinical
samples with degraded DNA and low viral load, complete LCR genomic regions of HPV204
were obtained only from two swab samples of the anal canal (ENA accession numbers
LT706550 and LT706551) with two HPV204 genetic variants identified. Whereas one HPV204
isolate exhibited 100% identity with the reference sequence (GenBank accession number
KP769769) in its LCR genomic region, the second HPV204 isolate harbored a single SNP
(A7145T) located within a putative E1-binding site (Table 4). Although the evolution of HPVs
is relatively slow in comparison to some other viruses, significant variations of distinct HPV
types were reported previously [2, 4, 63]. Thus, the genetic variability of HPV204 (number of
SNPs/deletions per genetic variant ranging from 0/510; 0.0% to 1/510; 0.2%) was probably
underestimated in our study and additional HPV204-positive samples from various anatomi-
cal locations should be evaluated to identify other potential SNPs and/or deletions.
In a previous study, Favre et al. [18] described only one SNP (A5793C) within a partial L1
sequence of HPV1, whereas they did not evaluate genetic variability within the LCR genomic
region. In our study, we obtained 18 complete LCR genomic regions of HPV1 (ENA accession
numbers LT706532–LT706549) (Table 4). In comparison to HPV204, HPV1 exhibited a
higher degree of genetic diversity within its LCR genomic region. In our study, we identified
five HPV1 genetic variants. Within the LCR genomic region of HPV1, we identified a total of
22 nucleotide positions that harbored SNPs/deletions. The number of SNPs/deletions per
genetic variant ranged from 1/979 (0.1%) to 19/979 (1.9%) and, except for a single cutaneous
wart tissue sample (sample ZU-7), the LCR genomic region of all HPV1-positive samples con-
tained a 15-bp long deletion (nucleotide positions 7,187 to 7,201), which was already described
previously (GenBank accession number U06714). Interestingly, 13/18 (72.2%) sequences
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obtained in our study exhibited 100% sequence identity with the U06714 HPV1 sequence
from GenBank, whereas four LCR sequences differed from this sequence only by a single SNP
(samples 1835, ZU-13, P00061 and 271). In our sample collection of cutaneous warts, we
observed a particularly prevalent genetic variant of HPV1, which was present in 13/16 (81.3%)
cutaneous warts tested and contained a 15-bp long deletion together with three SNPs. The sig-
nificance of this variant warrants further research, including testing of HPV1-positive samples
obtained from different geographic regions. Interestingly, all SNPs/deletions identified in LCR
genomic regions of HPV1 isolates were located outside viral functional domains and were not
associated with specific clinical manifestations or anatomical location.
Table 4. Genetic variability of the LCR genomic regions of HPV204, HPV1, and HPV63.
Nucleotide position in the LCR No. of
genetic
variants
No. of SNPs/deletions
per a complete LCR
genomic region (%)
HPV204 7
1
4
5
Reference KP769769 A
Anal swabs HPV204-LCR-
1
T N = 1 1/510 (0.2%)
HPV204-LCR-
2
* N = 1 0/510 (0.0%)
HPV1 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7
1 1 1 1 1 1 1 1 1 1 1 1 1 2 2 3 4 5 6 6 6 8
8 8 8 9 9 9 9 9 9 9 9 9 9 0 0 6 1 7 3 9 9 0
7 8 9 0 1 2 3 4 5 6 7 8 9 0 1 1 4 5 3 2 3 2
Reference Revised
V01116
A G A T T G T A T T G C T A T G C C G G G G
NC_001356a * * * * * * * * * * * * * * * * * * * C C *
U06714a - - - - - - - - - - - - - - - * * T T * * C
Nasopharyngeal
swab
HPV1-LCR-1 - - - - - - - - - - - - - - - * * T * * * C N = 1 17/979 (1.7%)
Cutaneous warts HPV1-LCR-2 * * * * * * * * * * * * * * * * * * * * * C N = 1 1/979 (0.1%)
HPV1-LCR-3 - - - - - - - - - - - - - - - T * T T * * C N = 1 19/979 (1.9%)
HPV1-LCR-4 - - - - - - - - - - - - - - - * * T T * * C N = 13 18/979 (1.8%)
HPV1-LCR-5 - - - - - - - - - - - - - - - * T T T * * C N = 2 19/979 (1.9%)
Anogenital wart HPV1-LCR-5 - - - - - - - - - - - - - - - * T T T * * C
HPV63 6 6 6 6 6 6 6 6 7 7 7 0 0
9 9 9 9 9 9 9 9 0 1 2 0 0
2 3 3 3 3 3 3 3 3 2 4 6 9
2 1 2 3 4 5 6 7 5 4 6 4 0
Reference X70828 A G T G A A T T G T A T C
Cutaneous warts HPV63-LCR-1 T - - - - - - - A G C C G N = 5 13/555 (2.3%)
Eyebrow hair
follicle
HPV63-LCR-2 * * * T * * * * A G C C G N = 1 6/555 (1.1%)
LCR, long control region; *, nucleotide matching with the PaVE reference sequence; -, nucleotide deletion at the respective nucleotide position.
a Obtained from GenBank.
https://doi.org/10.1371/journal.pone.0175892.t004
Molecular characterization of Mupapillomavirus types
PLOS ONE | https://doi.org/10.1371/journal.pone.0175892 April 20, 2017 12 / 17
A total of six complete LCR genomic regions of HPV63 were obtained in our study (ENA
accession numbers LT706552–LT706557) with two HPV63 genetic variants identified. As
shown in Table 4, all HPV63 isolates obtained from cutaneous warts were identical in their
LCR genomic regions and harbored six SNPs and a 7-bp long deletion (nucleotide positions
6,931–6,937). Similar to HPV1, the genetic variability of HPV63 was higher compared to
HPV204 with the number of SNPs/deletions per isolate ranging from 6/555 (1.1%) to 13/555
(2.3%). None of the SNPs/deletions were located within HPV63 functional domains. Interest-
ingly, because HPV63 isolate obtained from an eyebrow hair follicle (sample 612) differed
from the reference sequence (GeneBank accession number X70828) by only six SNPs, it is sug-
gested that HPV63 genetic variants might differ across different anatomical locations. How-
ever, our observation warrants further research on a larger collection of HPV63-positive
samples.
Our evaluation of genetic variability of Mu-PVs was limited. Due to the low quality of sam-
ples and low viral loads of Mu-PVs, we could only assess their genetic variability within the
LCR genomic regions. In order to provide better understanding of the prevalence and signifi-
cance of SNPs and deletions, sequencing of additional genomic regions or complete HPV
genomes should be performed. In addition, implementation of next-generation sequencing
techniques could aid in identification of rare genetic variants of Mu-PVs; however, high-qual-
ity DNA is required.
In conclusion, we presented a detailed molecular characterization of a novel Mu-PV type
HPV204 and compared it to the other members of the Mu-PV genus. The genome organiza-
tion of all Mu-PVs is similar, yet each of the three members of the Mu-PV genus exhibit spe-
cific molecular characteristics and harbor distinct functional domains. We have systematically
investigated the tissue tropism and potential clinical relevance of Mu-PVs by testing a large
collection of HPV-associated benign and malignant neoplasms as well as samples of clinically
normal mucosa and skin. Mu-PVs exhibit dual tissue tropism and mostly cause clinically latent
infections of the skin and mucosa. In addition, HPV1 and HPV63 are etiologically implicated
in the development of sporadic cases of cutaneous warts, whereas HPV204 does not appear to
cause any HPV-associated neoplasms. Lastly, we have shown that the LCR genomic regions of
HPV1 and HPV63 exhibit a high degree of genetic diversity; however, the clinical significance
of Mu-PV genetic variants warrants further research.
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